Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: two case reports.

Abstract

Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-alpha showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-alpha. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.

• Authors: H L Ee, G Yosipovitch, R Chan, B H Ong
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 149 Issue 3 Pg. 638-41 (Sep 2003) ISSN: 0007-0963 [Print] England
• PMID: 14511002 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Aminoquinolines
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage)
• Administration, Topical
• Adult
• Aminoquinolines (administration & dosage)
• Female
• Humans
• Imiquimod
• Middle Aged
• Vulvitis (drug therapy, pathology)